First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD), maximum tolerated dose (MTD) (if reached) and early signs of efficacy
of M4076 monotherapy in participants with solid tumors in dose escalation (Part 1A). Once the
recommended dose for expansion (RDE) is declared in Part 1A, a preliminary food effect
cohort, Part 1B, will follow at the RDE determined from Part 1A.